| Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca |
| Completed | 3 | 154 | RoW | Dapagliflozin, Placebo | Nanfang Hospital, Southern Medical University | Nonalcoholic Steatohepatitis | 03/24 | 03/24 | | |
OPTIMAR, NCT06317051: Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART) |
|
|
| Not yet recruiting | 3 | 300 | NA | Dapagliflozin 10mg Tab, FORXIGA, Pitavastatin 4 Mg Oral Tablet, Livazo, Rosuvastatin and Ezetimibe, Placebo | Kirby Institute | HIV Infections, Weight Gain | 07/25 | 12/26 | | |
EMPATHY, NCT05776043: Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure |
|
|
| Recruiting | 3 | 1364 | Europe | Empagliflozin 10 MG, Jardiance, Dapagliflozin 10 MG, Forxiga, Placebo, Placebo with switch to SGLT2 inhibitor | Medical University of Warsaw, Medical University of Vienna, Medical University of Graz, University Clinical Center of the Medical University of Warsaw, Jerzy Popiełuszko Bielański Hospital in Warsaw, Regional Polyclinical Hospital in Kielce, University Clinical Hospital Military Medical Academy, Central Veterans Hospital in Łódź, Medical University of Gdańsk, Autonomous Public Specialist Western John Paul II Hospital in Grodzisk Mazowiecki, Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, Poznan University of Medical Sciences, John Paul II Specialist Hospital in Kraków, Ludwik Rydygier Regional Polyclinical Hospital in Toruń, University Teaching Hospital in Białystok, Medical University of Silesia in Katowice | Acute Decompensated Heart Failure | 09/24 | 12/25 | | |
NCT06117137: The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus |
|
|
| Not yet recruiting | 3 | 150 | NA | SGLT2 inhibitor, Empagliflozin ,Dapagliflozin | Sohag University | Fatty Liver, Nonalcoholic | 10/24 | 10/24 | | |
| Recruiting | 3 | 450 | Europe | Dapagliflozin propanediol (FORXIGA™/FARXIGA™1), Placebo comparator | Assistance Publique - Hôpitaux de Paris, AstraZeneca | AMI, STEMI, NSTEMI, Left Ventricular Dysfunction | 01/26 | 01/26 | | |
| Recruiting | 3 | 430 | Europe | Dapagliflozin 10 mg, Farxiga, Placebo | Oslo University Hospital, Erasmus Medical Center, Skane University Hospital, Aarhus University Hospital, Karolinska University Hospital, Sahlgrenska University Hospital, Sweden | Heart Transplant Failure, Kidney Failure | 06/25 | 06/27 | | |
STENOTYPE, NCT05852704: SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF |
|
|
| Recruiting | 3 | 800 | Europe, RoW | Dapagliflozin 10mg Tab, Farxiga, Forxiga, Placebo Tab | Region Örebro County, Odense University Hospital, Aarhus University Hospital, Örebro University, Sweden, Sahlgrenska University Hospital, Sweden, Göteborg University, University of Leeds, Skane University Hospital, London School of Hygiene and Tropical Medicine, St. Anne's University Hospital Brno, Czech Republic, Mount Sinai Hospital, New York, University Hospital, Linkoeping, Icahn School of Medicine at Mount Sinai | Chronic Coronary Syndrome, Atrial Fibrillation | 12/27 | 12/28 | | |
DÁLIA, NCT05886088: Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus |
|
|
| Not yet recruiting | 3 | 597 | RoW | LID104, Dapagliflozin, Linagliptin | EMS | Type 2 Diabetes Mellitus | 05/26 | 01/27 | | |
| Recruiting | 3 | 102 | Europe | Dapagliflozin, Placebo | University Hospital Goettingen, German Research Foundation | Chronic Kidney Failure in Children and Young Adults | 09/26 | 12/26 | | |
| Recruiting | 3 | 3000 | RoW | Dapagliflozin 10mg Tab, SGLT2 inhibitor, Placebo | The George Institute, University Medical Center Groningen, Australian and New Zealand Intensive Care Society Clinical Trials Group | Acute Kidney Injury | 08/26 | 03/27 | | |
NCT05374291: The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD |
|
|
| Enrolling by invitation | 3 | 1500 | Europe, RoW | Dapagliflozin 10 mg/day (oral), Forxiga, Placebo | University Medical Center Groningen, AstraZeneca, Dutch Kidney Foundation | Kidney Disease, Chronic, Renal Transplant Failure, Heart Failure, Kidney Failure, Death | 01/27 | 01/27 | | |
NCT06087835: Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) |
|
|
| Recruiting | 3 | 1500 | Europe, Canada, Japan, US, RoW | Zibotentan/Dapagliflozin, Dapagliflozin | AstraZeneca | Chronic Kidney Disease With High Proteinuria | 06/27 | 06/27 | | |
NCT06286878: Pleiotropic Effects of Dapagliflozin in Patients With Acute Coronary Syndromes |
|
|
| Recruiting | 2/3 | 80 | RoW | Placebo, Dapagliflozin | University of Sao Paulo | Myocardial Infarction, Acute Coronary Syndrome, Diabetes, Ventricular Dysfunction | 12/24 | 07/25 | | |
| Completed | 2/3 | 454 | Europe | EDP1815, Dapagliflozin, Forxiga, Ambrisentan, Letairis, Volibris, Pulmonext, Standard of care | Cambridge University Hospitals NHS Foundation Trust | COVID-19 | 06/22 | 06/22 | | |
EDGE, NCT04400760: The Effect of Dapagliflozin on Platelet Function testinG Profiles in Diabetic PatiEnts. |
|
|
| Completed | 2/3 | 40 | RoW | DAPA Tx | The University of The West Indies | Platelet Dysfunction | 06/22 | 06/22 | | |
NCT05406505: Effect of Dapagliflozin in Patients With Acute Heart Failure (DAPA-RESPONSE-AHF) |
|
|
| Completed | 2/3 | 87 | RoW | Dapagliflozin 10mg Tab, Placebo | Mansoura University | Acute Heart Failure | 05/23 | 07/23 | | |
| Recruiting | 2/3 | 34 | Europe | Dapagliflozin 10mg Tab, Placebo | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, AstraZeneca | Chronic Kidney Disease, Diabetes Mellitus, Type 2, Hypertension | 09/24 | 09/24 | | |
DAKI-CKD, NCT05713851: Dapaglifozin to Avoid Acute Kindey Injury (AKI) to Chronic Kidney Disease (CKD) Transition: Study |
|
|
| Recruiting | 2/3 | 100 | RoW | Dapagliflozin | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Olynka Vega Vega, Noemi del Toro Cisneros, Miguel Ángel Martínez Rojas | AKI - Acute Kidney Injury, Biomarkers, Transition to CKD, CKD | 12/24 | 01/25 | | |
| Recruiting | 2/3 | 114 | US | Insulin, Semaglutide, Ozempic, Dapagliflozin, Farxigo, Placebo to Dapagliflozin | State University of New York at Buffalo, University of Glasgow, Juvenile Diabetes Research Foundation | Type 1 Diabetes Mellitus | 12/24 | 03/25 | | |
| Recruiting | 2/3 | 40 | RoW | Dapagliflozin 10 milligram, Placebo | Postgraduate Institute of Medical Education and Research | Diabetic Peripheral Neuropathy | 12/23 | 12/23 | | |
DAPAS, NCT05241431: Effect of Dapagliflozin on Myocardial and Renal Function Following Aortic Valve Stenosis Intervention |
|
|
| Recruiting | 2/3 | 106 | Europe | SGLT2 inhibitor, Placebo | University of Aarhus, Aarhus University Hospital | Aortic Stenosis, Left Ventricle Hypertrophied | 03/24 | 04/24 | | |
NCT05986136: Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease |
|
|
| Recruiting | 2/3 | 50 | RoW | Mesalamine, Dapagliflozin 10mg Tab | Mostafa Bahaa | Inflammatory Bowel Diseases | 08/24 | 07/28 | | |
| Recruiting | 2/3 | 108 | Europe | Dapagliflozin, Forxiga(R), Spironolactone, Aldactone(R), Spironolactone + Dapagliflozin, Forxiga(R) + Aldactone(R) | Universidade do Porto, Faculty of Medicine (FMUP), Centro Hospitalar Universitário de São João, E.P.E., Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E. | Heart Failure With Preserved Ejection Fraction | 09/24 | 12/24 | | |
| Recruiting | 2/3 | 270 | RoW | Dapagliflozin 10mg Tab, FORXIGA, Statins (Cardiovascular Agents), Atorvastatin, Pravastatin, Rosuvastatin, Platelet Antiaggregant, Clopidogrel, Acetylsalicylic acid, Antidiabetic, Sulfonylureas, Meglitinides, Biguanides, Thiazolidinediones, α-Glucosidase inhibitors, Inhibitors of dipeptidyl peptidase 4, Cycloset, Insulin glargine, Insulin lispro, Isophane insulin | Jaime Daniel Mondragon, Hospital General León, Hospital General de Zona IMSS N0. 21, University Medical Center Groningen | Stroke, Ischemic, Mild Cognitive Impairment, Dementia, Vascular, Metabolic Syndrome | 12/24 | 07/25 | | |
| Not yet recruiting | 2/3 | 150 | NA | Dapagliflozin 10mg Tab, metformin 1000 mg Tab, Placebo | Oman Ministry of Health | Obesity, Dapagliflozin Adverse Reaction, Weight Loss, Effect of Drug | 12/25 | 12/25 | | |
NCT06111443: Effect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation |
|
|
| Active, not recruiting | 2/3 | 196 | RoW | Dapagliflozin 10 mg [Farxiga] | Chang Gung Memorial Hospital | Atrial Fibrillation Recurrent, Catheter Ablation | 11/26 | 11/26 | | |
| Completed | 2b | 609 | Canada, Japan, US, RoW | MEDI3506, Placebo, Dapagliflozin | AstraZeneca | Diabetic Kidney Disease | 05/23 | 05/23 | | |
| Completed | 2b | 542 | Europe, Canada, Japan, US, RoW | Zibotentan, Dapagliflozin, Placebo | AstraZeneca, AstraZeneca AB | Chronic Kidney Disease | 06/23 | 06/23 | | |
| Completed | 2b | 153 | Europe, Canada, Japan, US, RoW | AZD9977, Dapagliflozin | AstraZeneca | Heart Failure, Chronic Kidney Disease | 09/23 | 09/23 | | |
PRESERVE, NCT05250752: Reduction of Peritoneal Glucose Uptake With Use of SGLT2 in Humans Undergoing Peritoneal Dialysis Treatment |
|
|
| Enrolling by invitation | 2a | 10 | Europe | Dapagliflozin 10 MG [Farxiga] | Holbaek Sygehus | End Stage Renal Disease, Peritoneal Dialysis Complication | 02/22 | 12/22 | | |
ACTRN12620001256965p: Chronic Myocardial Injury-Evaluating The Possible Role Of Sodium Glucose Co-Transporter 2 Inhibition (CHIRON) |
|
|
| Not yet recruiting | 2 | 120 | | | Flinders University of South Australia, AstraZeneca Pty.Ltd. | Chronic Myocardial Injury | | | | |
ACTRN12621001102864: A single-site study of the effectiveness of Dapagliflozin for diabetic patients admitted to the intensive care unit |
|
|
| Recruiting | 2 | 40 | | | Austin Health, Austin Health | Diabetes | | | | |
ACTRN12623000940673: A pilot trial of Dapagliflozin in patients at risk of acute kidney injury who are admitted to the intensive care unit |
|
|
| Recruiting | 2 | 40 | | | Prof Rinaldo Bellomo, Austin Health | Diabetes, Acute kidney injury | | | | |
2015-002963-40: Impact of treatment with Dapagliflozin in type 1 diabetic patients |
|
|
| Ongoing | 2 | 57 | Europe | Dapagliflozine, Film-coated tablet, Forxiga 10 mg | Dra Cristina Avendaño Sola, No | Type 1 diabetes Diabetes tipo 1, Diabetes Diabetes, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2017-001454-33: A 24-week study to evaluate the effect of dapagliflozin (10 mg once daily) plus exenatide (2.0 mg once weekly) on type 2 diabetic patients awaiting for bariatric surgery. Estudio de 24 semanas de duración para evaluar el efecto de la dapagliflozina (10 mg en dosis única diaria) asociada a exenatida (2,0 mg en dosis única semanal) en pacientes con diabetes mellitus tipo 2 candidatos a cirugía bariátrica. |
|
|
| Ongoing | 2 | 56 | Europe | Tablet, Powder and solution for solution for injection, Forxiga, Bydureon | Dr. Albert Lecube Torello, Astra Zeneca | Type 2 Diabetes mellitus Diabetes mellitus tipo 2, Diabetes mellitus Diabetes mellitus, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2017-003911-21: Dapagliflozin during exercise for the prevention of Hypoglycaemia in Type 1 diabetes |
|
|
| Not yet recruiting | 2 | 34 | Europe | Forxiga 10 mg film-coated tablets, Tablet, Forxiga 10 mg film-coated tablets | University of Oxford | Type 1 diabetes mellitus, Type 1 diabetes, Diseases [C] - Hormonal diseases [C19] | | | | |
2019-002262-12: Effect of the dapagliflozin drug on the glomerular hyperfiltration in nondiabeticobese patients. Efecto del fármaco dapagliflozina sobre la hiperfiltración glomerular ensujetos obesos sin diabetes. |
|
|
| Ongoing | 2 | 60 | Europe | Dapagliflozin, Tablet, Edistride | Hospital Universitari Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol | This study aims to demonstrate the hypothesis that treatment with dapagliflozin 10mg lowers in at least 10-20% of measured glomerular filtration rate (mGFR) in non-diabetic obese patients with glomerular hyperfiltration. Disminución de al menos 10-20% de la tasa de filtración glomerular medida (mTFG) en pacientes obesos sin diabetes con hiperfiltración glomerular tratados con dapagliflozina 10mg., Treatment of glomerular hyperfiltration by the usement of dapagliflozina. Tratamiento de la hiperfiltración glomerular gracias al uso de dapagliflozina., Diseases [C] - Symptoms and general pathology [C23] | | | | |
2020-004835-26: Single-center, randomized, controlled study to evaluate the effects of a six-month treatment with renal glucose transport inhibitor (SGLT2i) drugs on markers of senescence, inflammation and tubulointerstitial damage in the kidney of patients with chronic kidney disease with or without type 2 diabetes Studio monocentrico, randomizzato, controllato, per valutare gli effetti di un trattamento di sei mesi con farmaci inibitori del trasporto renale del glucosio (SGLT2i) sui marcatori di senescenza, infiammazione e danno tubulo-interstiziale nel rene dei pazienti con malattia renale cronica con o senza diabete tipo 2 |
|
|
| Ongoing | 2 | 38 | Europe | Dapagliflozin, [SGLT2i], Gastro-resistant tablet | IRCCS-A.O.U. SAN MARTINO-IST, AstraZeneca SpA | Chronic Kidney Deseas Insufficienza renale cronica, Chronic Kidney Deseas Malattia renale cronica, Body processes [G] - Reproductive physiologi cal processes [G08] | | | | |
2021-000726-10: Evaluating the short-term renal and systemic effects of Dapagliflozin in non-diabetic patients with stage IV CKD at risk of ESKD because of severe renal insufficiency and persistent proteinuria: A prospective, randomized, double-blind, placebo-controlled, cross-over study Valutazione degli effetti renali e sistemici a breve termine di Dapagliflozin, in pazienti non diabetici con CKD allo stadio IV a rischio di ESKD per grave insufficienza renale e proteinuria persistente: uno studio prospettico, randomizzato, in doppio cieco, controllato con placebo, con disegno cross-over |
|
|
| Not yet recruiting | 2 | 32 | Europe | dapagliflozin, [dapagliflozin], Film-coated tablet, FORXIGA - 10 MG - COMPRESSE RIVESTITE CON FILM- USO ORALE - BLISTER CALENDARIZZATO (ALU/ALU) - 28 COMPRESSE | IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI, AstraZeneca | Non-diabetic stage IV Chronic Kidney Disease (CKD) Insufficienza renale cronica non diabetica IV stadio, Non-diabetic stage IV Chronic Kidney Disease (CKD) Insufficienza renale cronica non diabetica IV stadio, Diseases [C] - Male diseases of the urinary and reproductive systems [C12] | | | | |
2021-001324-18: A Study to Assess the Effects of the drugs Zibotentan and Dapagliflozin in Patients with Elevated Levels of Protein in Urine |
|
|
| Not yet recruiting | 2 | 38 | Europe | zibotentan, Dapagliflozin, ZD4054, Dapagliflozin, Capsule, hard, Tablet, Forxiga | University Medical Center Groningen, Astra Zeneca | Patients with elevated Albuminuria, Patients with protein in the urine, Diseases [C] - Hormonal diseases [C19] | | | | |
STADIA-HFpEF, NCT04475042: Stratified Treatment to Ameliorate Diastolic Left Ventricular Stiffness in Heart Failure With Preserved Ejection Fraction |
|
|
| Recruiting | 2 | 26 | Europe | Dapagliflozin, Placebo | Mariëlle Scheffer, AstraZeneca | Heart Failure, Diastolic | 11/21 | 05/22 | | |
2020-004614-35: Trial to investigate the effect of SGLT-2 inhibitor in treating elevated blood glucose after acute abdominal surgery |
|
|
| Not yet recruiting | 2 | 24 | Europe | Capsule, forxiga | Ismail Gögenur, Centre for Surgical Science | Postoperative (stress) hyperglycemia in patients with no known diabetes after acute abdominal surgery, elevated blood glucose after acute abdominal surgery in patients with no history of diabetes, Body processes [G] - Metabolic Phenomena [G03] | | | | |
NCT04451837: Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology |
|
|
| Active, not recruiting | 2 | 200 | Europe | Semaglutide, Ozempic, Dapagliflozin, Forxiga | Region Skane, Göteborg University | Type2 Diabetes | 12/21 | 12/22 | | |
NCT05014594: Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT |
|
|
| Recruiting | 2 | 44 | RoW | Dapagliflozin (10Mg Tab) along with standard medical therapy, Placebo of dapaglifozin along with standard medical therapy | Postgraduate Institute of Medical Education and Research | Cirrhosis, Ascites Hepatic | 05/22 | 05/22 | | |
2020-000973-26: SOdium-Glucose cotransporter 2 inhibitor, ALDosterone AntagonIst, or both for heart failure with Preserved Ejection Fraction: a two-centre randomised three-treatment three-period crossover trial Inibidor do co-transportador de sódio e glucose 2, antagonista da aldosterona ou ambos para o tratamento da Insuficiência Cardíaca com Fração de Ejeção Preservada: Ensaio clínico aleatorizado cruzado de 3 tratamentos por 3 períodos, em 2 centros |
|
|
| Not yet recruiting | 2 | 108 | Europe | Not applicable, Not applicable, Film-coated tablet, Tablet, Forxiga 10 mg comprimidos revestidos por película, Aldactone 25 mg comprimidos | Faculdade de Medicina da Universidade do Porto, Faculdade de Medicina da Universidade do Porto | Heart Failure with Preserved Ejection Fraction, Heart Failure with Preserved Ejection Fraction, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2021-006787-25: The effects of dapagliflozin in patients with elevated blood pressure in the lungs |
|
|
| Not yet recruiting | 2 | 52 | Europe | Forxiga, Tablet, Forxiga (dapagliflozin) | Rigshospitalet The Heart Center, Rigshospitalet The Heart Center | Pulmonary arterial hypertensionChronic thromboembolic pulmonary hypertension, Elevated blood pressure in the lungs of unknown originChronic thrombi in the lungs with elevated blood pressure., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2020-002263-54: Dose-Response Effect, Efficacy, and Safety of AZD5718 in Reducing Albuminuria in Participants with Proteinuric Chronic Kidney Disease |
|
|
| Not yet recruiting | 2 | 632 | Europe | AZD5718, Dapagliflozin, AZD5718, Dapagliflozin, Tablet, Film-coated tablet, Forxiga | AstraZeneca AB, AstraZeneca AB | Proteinuric Chronic Kidney Disease, A gradual loss of kidney function over time accompanied by the presence of excess proteins in the urine, Diseases [C] - Symptoms and general pathology [C23] | | | | |
NCT05025735: Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer |
|
|
| Recruiting | 2 | 25 | US | Dapagliflozin 10Mg Tab | Saint Luke's Health System, Novartis Pharmaceuticals | Metastatic Breast Cancer, HER2-negative Breast Cancer | 12/22 | 07/23 | | |
2021-003674-32: A pilot study to evaluate the safety and efficacy of SGLT2 inhibitors in patients with cardiac amyloidosis |
|
|
| Not yet recruiting | 2 | 10 | Europe | Forxiga, Film-coated tablet, Forxiga | Region Västerbotten, Region Västerbotten, Umeå University, Hjärt- Lungfonden | Patients with cardiac amyloidosis., Patients with cardiac amyloidosis., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2020-000913-33: Personalized treatment of type 2 diabetes Personanpassad behandling av typ 2-diabetes |
|
|
| Not yet recruiting | 2 | 200 | Europe | Ozempic, Forxiga, Solution for injection in pre-filled pen, Film-coated tablet, Ozempic 0,25 mg solution for injection in prefilled pen, Forxiga 10 mg 98 film-coated tablets, Ozempic 0,5 mg solution for injection in prefilled pen, Ozempic 1,0 mg solution for injection in prefilled pen, Forxiga 10 mg 28 film-coated tablets | University of gothenburg, European Research Council | Type 2 diabetes, Type 2 diabetes, Diseases [C] - Hormonal diseases [C19] | | | | |
| Not yet recruiting | 2 | 54 | Europe | Dapagliflozin 10Mg Tab, Placebo, impedance cardiography, Applanation tonometry, post-ischemic hyperemia of forearm, haemodynamics parameters | University Hospital, Rouen, AstraZeneca | Renal Insufficiency, Chronic | 12/22 | 03/23 | | |
2021-004073-31: Treating mild kidney failure over 24 weeks in people with or without type 2 diabetes or high blood pressure |
|
|
| Not yet recruiting | 2 | 340 | Europe | dapagliflozin, Tablet, Forxiga | University Medical Center Groningen, AstraZeneca | Microalbuminuria, Mild kidney failure, Diseases [C] - Hormonal diseases [C19] | | | | |
TIMOTHY, NCT05268926: TreatIng Microalbuminuria Over 24 Weeks in Subjects With or Without Type 2 Diabetes or HYpertension |
|
|
| Terminated | 2 | 9 | Europe | Dapagliflozin 10Mg Tab, Placebo | University Medical Center Groningen, AstraZeneca | Albuminuria | 02/23 | 02/23 | | |
EPIK-B4, NCT04899349: Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant |
|
|
| Terminated | 2 | 2 | US, RoW | Alpelisib, Fulvestrant, Metformin XR, Dapagliflozin + metformin XR, Dapagliflozin | Novartis Pharmaceuticals | Breast Cancer | 05/23 | 05/23 | | |
ICARD, NCT05420285: Cardiometabolic Effects of Dapagliflozin in Heart Failure With Reduced or Mildly Reduced Ejection Fraction |
|
|
| Recruiting | 2 | 40 | Europe | Dapagliflozin, Forxiga | Assistance Publique - Hôpitaux de Paris | Heart Failure, Reduced Ejection Fraction | 09/23 | 05/24 | | |
2022-000420-38: Dapagliflozin in patients with Right Heart Failure (Dapa-RHF) |
|
|
| Not yet recruiting | 2 | 26 | Europe | Dapagliflozin, Film-coated tablet, FORXIGA | Universitätsmedizin Göttingen, AstraZeneca GmbH | Right heart failure defined as (criteria a-c must all be fulfilled):a) Reduced right ventricular systolic function or RV strain defined as at least one of the followingb) N-terminal pro-BNP (NT-proBNP) >125 pg/mlc) Clinical signs of right cardiac congestion or need for diuretic therapy to prevent signs of congestion, Dysfunction of the right heart structures (right ventricle, tricuspid valve apparatus and right atrium) resulting in impaired ability of right heart to perfuse lungs at normal central venous pressures, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Completed | 2 | 32 | Europe | Dapagliflozin 10Mg Tab, Placebo | Mario Negri Institute for Pharmacological Research, AstraZeneca | Chronic Kidney Diseases | 05/24 | 05/24 | | |
PROTECT, NCT06341842: Potential Protective Role of SGLT-2 Inhibitors for Chemotherapy-induced Cardiotoxicity |
|
|
| Recruiting | 2 | 316 | Europe | Dapagliflozin 10mg Tab, forxiga 10mg | Fondazione IRCCS Policlinico San Matteo di Pavia | Breast Cancer | 04/25 | 04/25 | | |
ACTRN12620001256965: Chronic Myocardial Injury-Evaluating The Possible Role Of Sodium Glucose Co-Transporter 2 Inhibition (CHIRON) |
|
|
| Active, not recruiting | 2 | 50 | | | Flinders University of South Australia, AstraZeneca Pty.Ltd. | Chronic Myocardial Injury | | | | |
| Recruiting | 2 | 50 | Canada | Dapagliflozin 10 MG, Placebo oral tablet | University Health Network, Toronto, Sunnybrook Health Sciences Centre, MOUNT SINAI HOSPITAL | Cardiovascular Risk Factor | 12/23 | 12/23 | | |
NCT06155604: SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease |
|
|
| Not yet recruiting | 2 | 150 | RoW | Dapagliflozin 10mg Tab, Farxiga, Forxiga, Standard maintenance therapy, Cellcept, Imuran | The University of Hong Kong | Lupus Nephritis, Chronic Kidney Diseases | 11/26 | 11/26 | | |
NCT06150924: Efficacy and Safety of Lorundrostat Alone, and in Combination With Dapagliflozin in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria |
|
|
| Recruiting | 2 | 80 | US | Part A - Lorundrostat QD + Dapaglifozin QD, Part A - Lorundrostat QD, Part B - Lorundrostat QD Open Label | Mineralys Therapeutics Inc. | Chronic Kidney Disease | 10/24 | 01/25 | | |
NCT05254626: Efficacy and Safety of Dapagliflozin in Patients With Non-alcoholic Steatohepatitis |
|
|
| Active, not recruiting | 2 | 100 | RoW | Dapagliflozin 10Mg Tab, Pioglitazone 30 mg | Cairo University | Non-alcoholic Steatohepatitis | 01/24 | 09/24 | | |
ZEAL UNLOCK, NCT06269484: A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK |
|
|
| Recruiting | 2 | 66 | Europe, Japan, US, RoW | Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet), Zibotentan + placebo (placebo matching dapagliflozin tablet), Zibotentan + dapagliflozin | AstraZeneca | Liver Cirrhosis | 01/25 | 01/25 | | |
NCT05792540: Clinical Study to Evaluate the Possible Efficacy of Dapagliflozin and Atorvastatin in Patients With Major Depressive Disorders |
|
|
| Recruiting | 2 | 75 | RoW | Fluoxetine 20 mg, Dapagliflozin 10mg Tab, Atorvastatin 80mg | Tanta University, Eman Ibrahim Elberri, Faculty of Pharmacy, Tanta University, Fedaa Abd El-monem Kamal El-deen Kotkata Faculty of Pharmacy, Tanta University, Manal Ali Mahrous Hamouda Faculty of Pharmacy, Menufia University | Depressive Disorder | 11/24 | 03/25 | | |
ARCADIA-HF, NCT04782245: Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List |
|
|
| Withdrawn | 2 | 80 | Europe | Dapagliflozin 10mg, Placebo | Hospices Civils de Lyon | End-stage Heart Failure | 04/24 | 04/24 | | |
ZODIAC, NCT05570305: Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria |
|
|
| Enrolling by invitation | 2 | 38 | Europe, Canada, US | Zibotentan, Dapagliflozin, Placebo, Dapagliflozin and Zibotentan | University Medical Center Groningen, AstraZeneca | Chronic Kidney Diseases | 04/24 | 09/24 | | |
NCT05305911: Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI |
|
|
| Recruiting | 2 | 80 | US | Dapagliflozin, Placebo | Minneapolis Heart Institute Foundation | Heart Attack, Enlarged Heart | 04/24 | 04/24 | | |
| Not yet recruiting | 2 | 20 | US | Dapagliflozin, BMS-512148, Forxiga® / Farxiga® | Jeffrey Zonder | Renal AL Amyloidosis | 04/26 | 04/27 | | |
MIRO-CKD, NCT06350123: Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease |
|
|
| Recruiting | 2 | 300 | Europe, Canada, Japan, US, RoW | Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg, Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg, Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin | AstraZeneca | Chronic Kidney Disease | 01/26 | 01/26 | | |
| Recruiting | 2 | 52 | Europe | Dapagliflozin 10 MG [Farxiga], Placebo | Mads Ersbøll | Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension | 06/24 | 09/24 | | |
NCT06427226: Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity |
|
|
| Not yet recruiting | 2 | 46 | RoW | Dapagliflozin 10mg Tab | Tanta University | Doxorubicin Induced Cardiomyopathy, Breast Cancer | 06/25 | 08/25 | | |
| Not yet recruiting | 2 | 60 | US | Dapagliflozin, MRI scan, CMR imaging | National Heart, Lung, and Blood Institute (NHLBI) | Myocardial Dysfunction, Heart Failure, Inflammation | 07/24 | 08/24 | | |
NCT04956809: Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure |
|
|
| Completed | 2 | 3 | US | Dapagliflozin 10Mg Tab, Placebo | University of Pennsylvania, Amgen | HFrEF | 06/23 | 06/23 | | |
NCT05710367: Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients |
|
|
| Not yet recruiting | 2 | 46 | NA | Dapagliflozin 10mg Tab, Placebo | Albina Nowak, MD | Fabry Disease | 08/24 | 08/24 | | |
| Recruiting | 2 | 195 | Europe, Canada, US, RoW | Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part A: zibotentan (dose B) + dapagliflozin, Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part B: placebo (matching zibotentan capsule) + dapagliflozin, Part B: zibotentan (dose A) + dapagliflozin, Part B: zibotentan (dose B) + dapagliflozin, Part B: zibotentan (dose C) + dapagliflozin | AstraZeneca, AstraZeneca AB | Liver Cirrhosis | 01/25 | 04/25 | | |
| Not yet recruiting | 2 | 334 | NA | GMRx-4 IR polypill - sitagliptin, dapagliflozin, metformin, Metformin | George Medicines PTY Limited, Brandon Biocatalyst, The George Institute | Type 2 Diabetes | 09/25 | 09/25 | | |
NCT06012266: Repurposing Empagliflozin and Dapagliflozin for Paediatric Heart Failure: Translational Approach and Dose Rationale |
|
|
| Not yet recruiting | 2 | 12 | Europe | Dapagliflozin tablet, Empagliflozin Tablets | Centre Hospitalier Universitaire Vaudois, Great Ormond Street Hospital for Children NHS Foundation Trust, University College, London | Heart Failure | 08/25 | 08/25 | | |
DapaBalci-Leap, NCT05884866: A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease. |
|
|
| Recruiting | 2 | 150 | Europe | Dapagliflozin 10mg Tab, Forxiga, Balcinrenone 50mg Capsule, Balcinrenone 100mg Capsule, Dapagliflozin matching Placebo, Balcinrenone 50mg matching Placebo, Balcinrenone 100mg matching Placebo | Klinikum Nürnberg | Chronic Renal Failure, Mechanistic Effects of SGLT2 Inhibition and/ or MR Antagonism on Body Fluid and Electrolyte Homeostatis | 01/25 | 01/25 | | |
| Recruiting | 2 | 108 | Europe | Dapagliflozin 10 MG, Forxiga 10 MG, Placebo | Medical University of Vienna, Vienna Dialysis Center | Kidney Failure, Hemodialysis, Diabetes Mellitus, Type 2, Chronic Kidney Disease, Left Ventricular Hypertrophy | 04/25 | 09/25 | | |
DECODE-CKD, NCT05359263: Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients With CKD |
|
|
| Recruiting | 2 | 222 | Europe | Dapagliflozin 10 mg, Placebo | Tor Biering-Sørensen | Chronic Kidney Diseases | 04/25 | 04/25 | | |
NCT05914857: Evaluation of the Safety and Efficacy of SGLT2 Inhibitors in Pre-diabetic Patients |
|
|
| Not yet recruiting | 2 | 120 | RoW | Dapagliflozin 10mg Tab, Dapagliflozin Tablets, lifestyle interventions | Yangjin, Peking University Third Hospital | Prediabetic State, Impaired Fasting Glucose, Impaired Glucose Tolerance | 06/25 | 12/25 | | |
NCT04640493: SGLT2-Inhibitors for Sleep Apnea in Heart Failure |
|
|
| Withdrawn | 2 | 20 | US | Dapagliflozin, FARXIGA, WatchPat | Columbia University | Heart Failure, Sleep Disordered Breathing | 08/25 | 08/25 | | |
NCT05058859: Long Term Clinical Efficacy of Sodium-glucose Cotransporter-2 (SGLT-2) Inhibitor in Cystinurics |
|
|
| Not yet recruiting | 2 | 10 | US | Dapagliflozin, FARXIGA | University of California, San Francisco | Cystinuria | 08/25 | 12/26 | | |
HALLMARK, NCT05938712: The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients |
|
|
| Recruiting | 2 | 20 | Canada | Dapagliflozin 10 MG, FARXIGA, Semaglutide, 1.0 mg/mL, OZEMPIC | University Health Network, Toronto | Kidney Transplant Recipients | 10/25 | 10/25 | | |
| Recruiting | 2 | 60 | US | Dapagliflozin | Yale University, American Heart Association | Cardiorenal Syndrome | 05/26 | 05/26 | | |
NCT04818034: The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study |
|
|
| Recruiting | 2 | 10 | US | Dapagliflozin, FARXIGA | University of California, San Francisco | Cystinuria | 12/25 | 06/26 | | |
2020-005842-41: BIOAVAILABILITY STUDY OF DAPAGLIFLOZIN 10 mg FORMULATIONS IN HEALTHY VOLUNTEERS UNDER FED CONDITIONS RAZISKAVA BIOLOŠKE UPORABNOSTI ENEGA POSAMIČNEGA ODMERKA FORMULACIJ DAPAGLIFLOZINA 10 mg, PRI ZDRAVIH PROSTOVOLJCIH PO OBROKU HRANE |
|
|
| Ongoing | 1/2 | 24 | Europe | Test 1: Dapagliflozin 10 mg film-coated tablets, Test 2: Dapagliflozin 10 mg film-coated tablets, Reference : Forxiga 10 mg film coated tablets, NA, Film-coated tablet, Forxiga film coated tablets | KRKA, d.d., Novo mesto, KRKA d.d. | Healthy voluneers Zdravi prostovoljci, NA NA, Not possible to specify | | | | |
| Completed | 1/2 | 46 | US | Dapagliflozin, Farxiga, Placebo | Jeff Burns, MD | Alzheimer Disease | 07/22 | 07/22 | | |
NCT04401904: SGLT2 Inhibition in Older Obese Adults With Pre-diabetes |
|
|
| Completed | 1/2 | 20 | US | Dapagliflozin 10 mg, Farxiga, Nutritional counseling | The University of Texas Health Science Center at San Antonio, National Institute on Aging (NIA) | Aging | 09/22 | 09/22 | | |
NCT06113900: Assessment of Safety and Efficacy of SGLT2is Among LN Patients |
|
|
| Not yet recruiting | 1/2 | 50 | RoW | Dapagliflozin 10mg Tab orally once daily, Empagliflozin 10 mg tab orally once daily | Ain Shams University | Lupus Nephritis | 12/24 | 01/25 | | |
MOJAVE, NCT05965934: Management of Volume Overload HF Patients by Individual DSR Treatment adJustment-a clinicAl inVestigation of InfusatE2.0 |
|
|
| Recruiting | 1/2 | 33 | US | Direct Sodium Removal Infusate 2.0, SGLT-2 inhibitor (dapagliflozin) | Sequana Medical N.V. | Heart Failure, Volume Overload | 12/24 | 06/25 | | |
NCT05719714: Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease |
|
|
| Recruiting | 1/2 | 60 | US | Dapagliflozin 10 MG [Farxiga] | Northwestern University, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) | Chronic Kidney Diseases, Heart Failure With Preserved Ejection Fraction, Kidney Diseases, Heart Failure | 03/26 | 09/26 | | |
NCT04544319: Clinical Trial to Compare the PK of the Fixed-dose Combinations and Each Component of Gemigliptin/Dapagliflozin 50/10 mg |
|
|
| Not yet recruiting | 1 | 44 | NA | Zemiglo 50mg and Forxiga 10mg, zemiglo and Forxiga, Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg | LG Chem | T2DM | 03/21 | 07/21 | | |
| Completed | 1 | 22 | US | Dapagliflozin 5mg, Farxiga, Placebo Oral Tablet | University of California, San Diego, Juvenile Diabetes Research Foundation | Type1 Diabetes Mellitus | 06/21 | 11/21 | | |
NCT05105698: Food-effect Bioavailability of Gemigliptin and Dapagliflozin 50/10 mg |
|
|
| Not yet recruiting | 1 | 28 | NA | gemigliptin and dapagliflozin 50/10 mg film-coated tablet (Fasting), DPP-4 inhibitor and SGLT-2 inhibitor combination, gemigliptin and dapagliflozin 50/10 mg film-coated tablet (fed) | LG Chem | Healthy Volunteers | 02/22 | 09/22 | | |
Dapa-Stress, NCT04234867: Study to Explore the Effect of Dapagliflozin and Stress in Adolescent and Adult Subjects With Type 1 Diabetes (T1D) |
|
|
| Terminated | 1 | 2 | Europe | Dapagliflozin, Forxiga, Placebo oral tablet, Control, Stress, Synacthen, Placebo Stress, Stress Control | Kinderkrankenhaus auf der Bult | Type 1 Diabetes, Diabetic Ketoacidosis | 08/22 | 08/22 | | |
NCT05217654: Trial to Investigate the Effect of Dapagliflozin on Ischemia Reperfusion Induced Endothelial Dysfunction |
|
|
| Recruiting | 1 | 32 | Europe | Dapagliflozin 10mg, Forxiga 10mg Tabletten, Placebo, Placebo tablets | Medical University of Vienna | Reperfusion Injury, Vascular Complications | 02/23 | 08/23 | | |
NCT05429593: A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet |
|
|
| Completed | 1 | 152 | Europe | Semaglutide, Dapagliflozin, Semaglutide/dapagliflozin | Novo Nordisk A/S | Healthy Volunteers | 04/23 | 04/23 | | |
NCT04806633: Dapagliflozin to Prevent the Incidence of Contrast Induced Nephropathy After Heart Catheterization and Percutaneous Coronary Intervention |
|
|
| Not yet recruiting | 1 | 1722 | Europe | Dapagliflozin 5mg, Placebo | G.Gennimatas General Hospital, 2nd Department of Cardiology, "Attikon" University Hospital, National and Kapodistrian University of Athens | Left Cardiac Catheterization, Percutaneous Coronary Intervention, Acute Kidney Injury, Sodium-glucose Co-transporter 2 Inhibitors | 09/23 | 12/23 | | |